NMD4C Hosts 2nd Annual Basic Research Summer School at York University!

On May 7–8, 2025, the NMD4C preclinical research team, led by Dr. Christopher Perry, hosted the second annual Basic Research Summer School at York University. This national training event brought together 30 graduate students and postdoctoral fellows from across Canada for an intensive two-day program dedicated to advancing neuromuscular research skills and connections.

The Summer School kicked off with trainee flash talks, followed by lectures featuring patient partners, early-career and senior scientists, and members of industry. An evening networking dinner and career panel capped off the first day, offering insight into diverse research paths.

On Day 2, trainees participated in one of two full-day workshops: Myofibre Isolation and Analysis led by Dr. Anthony Scimè, or Rodent Muscle Function Assessment led by Dr. Arthur Cheng. These sessions provided rare, hands-on exposure to specialized wet lab techniques. The day concluded with an informal networking dinner to build community and spark collaboration.

Following the Summer School, many participants remained at York University to attend and present posters at Muscle Health Awareness Day —an exciting opportunity to connect with a broader community of muscle researchers.

This event would not have been possible without the tireless efforts of our organizing team: Dr. Christopher Perry (Chair), Dr. Anthony Scimè, Dr. Arthur Cheng, Adam Charnaw, Linda Niksic, Dr. Emma Sutton, Dr. Marine Christin, Dr. Erin Beattie, and James Davis.

We are grateful to our speakers and panelists, volunteers, and workshop instructors, and we extend our sincere thanks to our sponsors: The Stem Cell Network, Aurora Scientific Inc., Kent Scientific Corporation, and York University’s Vice-President Research & Innovation Office. Special thanks also go to our event photographer, Cheryl Corson.

Looking ahead, we’re thrilled to announce that next summer’s Summer School will be held in Ottawa. Stay tuned to our event webpage for updates!

20250508_151830 (1)

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.